Cargando…

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer

BACKGROUND: Ovarian cancer (OC) is amongst the most lethal of common cancers in women. Lacking in specific symptoms in the early stages, OC is predominantly diagnosed late when the disease has undergone metastatic spread and chemotherapy is relied on to prolong life. Platinum-based therapies are pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howard, David, James, David, Garcia-Parra, Jezabel, Pan-Castillo, Belen, Worthington, Jenny, Williams, Nicole, Coombes, Zoe, Rees, Sophie Colleen, Lutchman-Singh, Kerryn, Francis, Lewis W., Rees, Paul, Margarit, Lavinia, Conlan, R. Steven, Gonzalez, Deyarina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732436/ https://www.ncbi.nlm.nih.gov/pubmed/36505806 http://dx.doi.org/10.3389/fonc.2022.1014280

Ejemplares similares

Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer
por: Howard, David, et al.
Publicado: (2021)

Elucidating Novel Targets for Ovarian Cancer Antibody–Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity
por: Onyido, Emenike Kenechi, et al.
Publicado: (2023)

Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells
por: Quintela, Marcos, et al.
Publicado: (2023)

Chronic Urinary Infection in Overactive Bladder Syndrome: A Prospective, Blinded Case Control Study
por: Khan, Zainab, et al.
Publicado: (2021)

In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer
por: Quintela, Marcos, et al.
Publicado: (2023)

Mechanomimetic 3D Scaffolds as a Humanized In Vitro Model for Ovarian Cancer
por: Paradiso, Francesca, et al.
Publicado: (2022)

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
por: Riess, Christin, et al.
Publicado: (2020)

Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer
por: Healey, Gareth D., et al.
Publicado: (2019)

Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
por: Saqub, Hera, et al.
Publicado: (2020)

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
por: Gojo, Ivana, et al.
Publicado: (2013)

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
por: Desai, Brijal M., et al.
Publicado: (2013)

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2016)

Therapeutic Potential of Microalgae-Derived Bioactive Metabolites Is Influenced by Different Large-Scale Culture Strategies
por: Garcia-Parra, Jezabel, et al.
Publicado: (2022)

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia
por: Flynn, Joseph, et al.
Publicado: (2015)

Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11
por: Younas, Kinza, et al.
Publicado: (2019)

Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma
por: Nelson, Luke J, et al.
Publicado: (2022)

Progesterone Metabolism by Human and Rat Hepatic and Intestinal Tissue
por: Coombes, Zoe, et al.
Publicado: (2021)

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
por: Mita, Monica M, et al.
Publicado: (2017)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

Liquid crystal delivery of ciprofloxacin to treat infections of the female reproductive tract
por: Pisano, Simone, et al.
Publicado: (2019)

Progestogens Are Metabolized by the Gut Microbiota: Implications for Colonic Drug Delivery
por: Coombes, Zoe, et al.
Publicado: (2020)

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
por: Nemunaitis, John J, et al.
Publicado: (2013)

Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy
por: Yuan, Qian, et al.
Publicado: (2022)

Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia
por: Pariury, Holly, et al.
Publicado: (2023)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

Size, Composition, and Support-Doping Effects on Oxygen Reduction Activity of Platinum-Alloy and on Non-platinum Metal-Decorated-Graphene Nanocatalysts
por: Lozano, Tamara, et al.
Publicado: (2019)

Bcl-x(L) inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas
por: Rello-Varona, Santi, et al.
Publicado: (2019)

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib
por: Ke, Changhong, et al.
Publicado: (2020)

A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer
por: Murphy, Adrian G., et al.
Publicado: (2020)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer
por: Shen, Xiao, et al.
Publicado: (2023)

iNOS Activation Regulates β-catenin Association with Its Partners in Endothelial Cells
por: Gonzalez, Deyarina, et al.
Publicado: (2012)

Editorial: Exosomes as Therapeutic Systems
por: Corradetti, Bruna, et al.
Publicado: (2021)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner
por: Varadarajan, Shankar, et al.
Publicado: (2015)

A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development
por: Healey, Gareth D., et al.
Publicado: (2019)

Noisy Cell-Size-Correlated Expression of Cyclin B Drives Probabilistic Cell-Size Homeostasis in Fission Yeast
por: Patterson, James O., et al.
Publicado: (2019)

Low dose dinaciclib enhances doxorubicin-induced senescence in myeloma RPMI8226 cells by transformation of the p21 and p16 pathways
por: Tang, Hailong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cni1q3ulfmljc55nuk0gvbhipt